Jaguar Health, Inc.
$0.41
▼
-1.48%
2026-04-21 07:38:00
jaguar.health
NCM: JAGX
Explore Jaguar Health, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.34 M
Current Price
$0.41
52W High / Low
$15.48 / $0.31
Stock P/E
—
Book Value
$0.85
Dividend Yield
—
ROCE
-91.43%
ROE
-628.65%
Face Value
—
EPS
$-22.97
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
—
Debt / Equity
5.01
Current Ratio
0.5
Quick Ratio
0.29
Forward P/E
-0.06
Price / Sales
0.4
Enterprise Value
$48.53 M
EV / EBITDA
-1.12
EV / Revenue
4.22
Rating
None
Target Price
$7.5
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Roivant Sciences Ltd. | $29.41 | — | $21.16 B | — | -21.06% | -19.14% | $30.33 / $10.01 | $6.02 |
| 2. | AtaiBeckley Inc. | $4.9 | — | $1.47 B | — | -76% | -3.9% | $6.75 / $1.29 | $0.61 |
| 3. | MiNK Therapeutics, Inc. | $12.82 | — | $63.66 M | — | 859.68% | 57.3% | $76 / $6.34 | $-3.02 |
| 4. | MeiraGTx Holdings plc | $10.53 | — | $857.63 M | — | -86.95% | -3.68% | $11.85 / $4.55 | $-0.07 |
| 5. | Black Diamond Therapeutics, Inc. | $3.05 | 7.84 | $175.3 M | — | 15.61% | 22.88% | $4.94 / $1.31 | $1.96 |
| 6. | Grace Therapeutics, Inc. | $4.59 | — | $71.03 M | — | -23.81% | -10.22% | $5.18 / $2 | $4.19 |
| 7. | Lixte Biotechnology Holdings, Inc. | $3.44 | — | $39.91 M | — | -431.9% | -1.02% | $6.26 / $0.64 | $0.9 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 3.23 M | 3.08 M | 2.98 M | 2.21 M | 3.51 M | — |
| Operating Profit | -20.44 M | -7.24 M | -8.01 M | -9.42 M | -8.16 M | — |
| Net Profit | -23.06 M | -9.5 M | -10.41 M | -10.46 M | -9.92 M | — |
| EPS in Rs | -1.86 | -0.77 | -0.84 | -0.84 | -0.8 | -26.29 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 11.51 M | 11.69 M | 9.76 M | 11.96 M |
| Operating Profit | -45.11 M | -30.83 M | -33.92 M | -34.41 M |
| Net Profit | -53.43 M | -38.49 M | -41.3 M | -47.45 M |
| EPS in Rs | -4.3 | -3.1 | -3.33 | -3.82 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 38.32 M | 53.42 M | 50.76 M | 47.45 M |
| Total Liabilities | 57.01 M | 46.93 M | 45.87 M | 48.81 M |
| Equity | -17.29 M | 7.29 M | 4.96 M | -0.66 M |
| Current Assets | 20.34 M | 32.2 M | 27.96 M | 22.32 M |
| Current Liabilities | 40.65 M | 19.7 M | 13.99 M | 30.34 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -23.69 M | -29.38 M | -33.24 M | -33.1 M |
| Investing CF | -0.04 M | -0.23 M | 0 M | -1.68 M |
| Financing CF | 23.67 M | 31.2 M | 34.23 M | 23.18 M |
| Free CF | -23.73 M | -29.61 M | -33.24 M | -34.78 M |
| Capex | -0.04 M | -0.23 M | — | -1.68 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 19.75% | -18.36% | — | — |
| Earnings Growth % | 6.8% | 12.97% | — | — |
| Profit Margin % | -329.3% | -423.11% | -396.91% | — |
| Operating Margin % | -263.76% | -347.51% | -287.85% | — |
| Gross Margin % | 83.27% | 79.13% | 83.11% | — |
| EBITDA Margin % | -313.65% | -339.42% | -279.19% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-03-24 | 1:0.04 |
| 2024-05-23 | 1:0.0166667 |
| 2023-01-23 | 1:0.0133333 |
| 2021-09-08 | 1:0.333333 |